Management Team
Board of Directors
Scientific Advisory Board
Clinical Advisors
R&D Leaders
Targeted Medicine
Strategic Alliances
Research Ethics
Our History
Omacetaxine mepesuccinate
QuinamedŽ
CXS-299
Cancer Discovery Program
Drug Discovery & Preclinical Development
Genomic Clinical Development
Financial Reports
Corporate Governance
Presentation Archive
Information Request
2008 Press Releases
2007 Press Releases
2006 Press Releases
2005 Press Releases
Investor Events Calendar
Chronic Myelogenous Leukemia
Myelodysplastic Syndrome
Prostate Cancer
Culture
Current Openings
April 15, 2008
ChemGenex Reports Oral Bioavailability of Omacetaxine and Expands on Mechanism of Action
April 14, 2008
ChemGenex Confirms Planned NDA Rolling Submission for Omacetaxine Following Meeting with U.S. FDA
April 01, 2008
ChemGenex Investigators Present Data on Clinical Activity of Omacetaxine in Imatinib-Resistant Chronic Myeloid Leukemia Patients with the T315I Mutation at International Leukemia Conference
© 2005 ChemGenex Pharmaceuticals |
Terms of Use
built@zoomedia
